Comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication

被引:21
作者
Farup, PG
Tholfsen, J
Wetternus, S
Torp, R
Hoie, O
Lange, OJ
机构
[1] Norwegian Univ Sci & Technol, Unit Appl Clin Res, N-7034 Trondheim, Norway
[2] Oppland Cent Hosp, Gjovik, Norway
[3] Oppland Cent Hosp, Dept Med, Lillehammer, Norway
[4] Kongsvinger Hosp, Dept Med, Kongsvinger, Norway
[5] Hedmark Cent Hosp, Dept Med, Hamar, Norway
[6] Aust Agder Cent Hosp, Dept Med, Arendal, Norway
[7] Molde Hosp, Dept Med, Molde, Norway
关键词
controlled clinical trials; drug therapy; Helicobacter pylori; omeprazole; proton-pump inhibitors; ranitidine bismuth citrates;
D O I
10.1080/003655202762671233
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Regimens with ranitidine bismuth citrate (RBC) or omeprazole (O) are effective in eradicating Helicobacter pylori. This randomized, open, multicentre trial compares three different regimens with these drugs. Methods: Consecutive H. pylori +ve outpatients were included. The alternative regimens were: 1) O 20 mg, clarithromycin (C) 250 mg and metronidazole (M) 500 mg (O.C.M), 2) RBC 400 mg, C 250 mg and M 500 mg (RBC.C.M), 3) RBC 400 mg, tetracycline (T) 1000 mg and M 500 mg [RBC.T.M]. All drugs were given twice daily for 7 days. H. pylori infection was assessed with H. pylori urea breath tests. Results: 426 H. pylori +ve patients were included (mean age 58 years [range 18-88], male/female: 244/182). The eradication rates (intention to treat) in the O.C.M, RBC.C.M and RBC.T.M groups were 117/137 (85%), 141/146 (97%) and 117/143 (82%), respectively (P < 0.001, overall assessment). There were no significant differences in side effects between the alternatives. Conclusion: In this trial, RBC.C.M was the most effective one, it was well tolerated and compliance was satisfactory. RBC.T.M is an alternative to regimens with clarithromycin.
引用
收藏
页码:1374 / 1379
页数:6
相关论文
共 23 条
[1]   Regular review -: Treatment of Helicobacter pylori infection [J].
de Boer, WA ;
Tytgat, GNJ .
BRITISH MEDICAL JOURNAL, 2000, 320 (7226) :31-34
[2]  
FARUP PG, 1992, ALIMENT PHARM THERAP, V6, P179
[3]   Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole:: a meta-analysis of eradication of Helicobacter pylori [J].
Gisbert, JP ;
González, L ;
Calvet, X ;
García, N ;
López, T ;
Roqué, M ;
Gabriel, R ;
Pajares, JM .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (10) :1319-1328
[4]   Ranitidine bismuth citrate therapy regimens for treatment of Helicobacter pylori infection:: A review [J].
Gisbert, JP ;
Pajares, JM ;
Valle, J .
HELICOBACTER, 1999, 4 (01) :58-66
[5]  
Gisbert JP, 2000, ALIMENT PHARM THER, V14, P1141
[6]  
Houben MHMG, 1999, ALIMENT PHARM THER, V13, P1047
[7]   A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole [J].
Janssen, MJR ;
Van Oijen, AHAM ;
Verbeek, ALM ;
Jansen, JBMJ ;
De Boer, WA .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (05) :613-624
[8]  
Kung NNS, 1999, AM J GASTROENTEROL, V94, P721, DOI 10.1111/j.1572-0241.1999.00942.x
[9]  
Malfertheiner P, 2002, ALIMENT PHARM THER, V16, P167, DOI 10.1046/j.1365-2036.2002.01169.x
[10]  
Malfertheiner P, 1997, GUT, V41, P8